{"name":"Scilex Holding","slug":"scilex","ticker":"SCLX","exchange":"NASDAQ","domain":"scilexholding.com","description":"Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation","hq":"Palo Alto, CA","founded":0,"employees":"34","ceo":"Jaisim Shah","sector":"Pain Management / Specialty Pharma","stockPrice":6.76,"stockChange":0.18,"stockChangePercent":2.74,"marketCap":"$48M","metrics":{"revenue":56590000,"revenueGrowth":-67.8,"grossMargin":65,"rdSpend":9641000,"netIncome":-72807000,"cash":10981000,"dividendYield":0,"peRatio":9.3,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"ZTlido patent cliff ($10.0M at risk)","drug":"ZTlido","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Qtrypta patent cliff ($50.0M at risk)","drug":"Qtrypta","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Scilex Holding Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Scilex Holding reported fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $24.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-06","type":"deal","headline":"Scilex Holding Announces Exclusive Distribution Agreement with Avella Specialty Pharmacy","summary":"Scilex Holding announced an exclusive distribution agreement with Avella Specialty Pharmacy to distribute its pain management products.","drugName":"","sentiment":"positive"},{"date":"2022-06-30","type":"regulatory","headline":"Scilex Holding Receives FDA Approval for Qtrypta for the Treatment of Migraine","summary":"Scilex Holding received FDA approval for Qtrypta for the treatment of migraine.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPdUFNUGpfTnp6NkVRLXhta3N1RXV0Sm9XN0tWMWtTNnRBSUI0dXlUd2FyMTNNM3Y2WFRTYlRKTGJvVnFIR3loNUUxQm01M1dPYlVySHNSaG4taDlUdkFwLVJvZ2FOczB0RHFiWFlHajZUQUEwZWZrMEtuQTJpLUNLM0pvRzVXNU1yOVVUM0tYQ0hyOTRpMXhOZjBLLWZHMGR1VEgtYXJGeHRWTWh4ZEVXMlpZUmNRU1FXR2VLLTliRnkzbHBWZnUxSFN3MTZ6YUVvTHQ5Z3RB?oc=5","date":"2026-02-21","type":"pipeline","source":"The Globe and Mail","summary":"Scilex Grants Oramed New Warrant in Financing Agreement - The Globe and Mail","headline":"Scilex Grants Oramed New Warrant in Financing Agreement","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-10","type":"pipeline","source":"simplywall.st","summary":"Not Many Are Piling Into Scilex Holding Company (NASDAQ:SCLX) Stock Yet As It Plummets 26% - simplywall.st","headline":"Not Many Are Piling Into Scilex Holding Company (NASDAQ:SCLX) Stock Yet As It Plummets 26%","sentiment":"neutral"},{"date":"2025-12-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-17","type":"pipeline","source":"simplywall.st","summary":"Retail investors invested in Scilex Holding Company (NASDAQ:SCLX) copped the brunt of last week's US$12m market cap decline - simplywall.st","headline":"Retail investors invested in Scilex Holding Company (NASDAQ:SCLX) copped the brunt of last week's US$12m market cap decl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxORWl2VjNhWnVtLUVNUWdNM1MxR2prM0liTzFmWmY0TV9HQXhRM1c4SDdqVmNzSUl0MFQ2Q3ZaVVZUQ3VaZnZDaWhxVWFILVBaMTlULUhFRlZCaS1TTnRPNkNPRDNCY1hUd2pIUWc2NDJEOUFYTFhreFZReUJLUmh2Y2JWUk1ObVk5cDNXRkhoM0hzekZFNGpKb0x0SnBtaUo1azN0T1o1cDRtTGZNU2lMRE9Fc3M3NW96QTlr?oc=5","date":"2025-11-04","type":"trial","source":"Stock Titan","summary":"Scilex (NASDAQ: SCLX) licenses Datavault AI to tokenize data; milestones up to $2.55B - Stock Titan","headline":"Scilex (NASDAQ: SCLX) licenses Datavault AI to tokenize data; milestones up to $2.55B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNc2lIWlVjUVBhMFh3ZFV4MWNHV1VsUHVmYmduT2VsSlVPZnZLU0pVRXZkeTA2M2NQREdkeGg5Vk1xTkowWDJQdFprUjB2ZVlwOXp5S0JnTnpicnJrQUdjWXFHUEVycGk4aHFGZmVaWUZTcjVtSzBITWlmbDVPcmtXZEc4SWVJYWwxcmM3Si1GcU1QM3pyZ184dWVPamNDVVpRd21fS3Zpd1prbnRkak9UNlZoSGhHSEtOaU1CejFOdlE0OWhwUHduVmlZdDc5VEtGdDUzYWZGczV4TzZuZE03cGF30gHnAUFVX3lxTE10OFJlUHhlbnlXMnVKMHhaVjVhTXNSa2g4MWl6eG54RzhlMTVpbGlDa3htaFBiSVlScFlLUGdtMU5acG5CeVF2Y2Z6b0ZQR3UyNk1veDhGcXBGa2dXRmFSZUwxSHNhUUlLbGp6MjBBR3JFVHVaZmNIcWZyQ2hFUnhoREJrNS1uU0gyeHRDdFlPUUVxckc0THRsdUZPU0FVS0djT3gzU1doWHNJaktybGdKZUxfYWdRSkh4dW1HdnRBZmFSRVRNTjBULUNIWFI0djJ3RW9Wdm84c3E2TnlPWTc1WkhYSHdXMA?oc=5","date":"2025-10-28","type":"earnings","source":"simplywall.st","summary":"When Can We Expect A Profit From Scilex Holding Company (NASDAQ:SCLX)? - simplywall.st","headline":"When Can We Expect A Profit From Scilex Holding Company (NASDAQ:SCLX)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNQVJMc2Zlb01ZckNEdEJ4bUF6bFlmUldkRGgyVGpOQmNEWnpQX3EtWTA2Qm5iWjFTZzVzbDFheXo1amhaeUk3bnJxeWYyb2JJd040RmNTc3QyLUp2ZkFEcmpoRjJNVmNLUDBzc3dUc1ZqajhmSTVsaHh6SHhZMVV3cU12TWlxYm13cFZtOXlDWnVnRlhKZWRvQWZ6SDhldEtnXzR2ZG1oMGY3dHI5LTdiVzdtMksyX2NkSHpYSllPQ2xJQ1VLY0VWSEdZMk1Uc3FPRXdQX0NPZzdUX1NaUU5yTg?oc=5","date":"2025-10-01","type":"pipeline","source":"Quiver Quantitative","summary":"Scilex Holding Company Completes Repurchase of 3.13 Million Warrants from Oramed Pharmaceuticals for $13 Million - Quiver Quantitative","headline":"Scilex Holding Company Completes Repurchase of 3.13 Million Warrants from Oramed Pharmaceuticals for $13 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQcFlGQUJEVU81RTRQTUEwVnpfYkVDVkRGNEFjajdfclZ6dEtiLS03amtXSjllYzNybk0zTUxvUWp2T3RXOU1NZW96ZEdiRGpKZDR3cXNwRG5qc1dSbXdNWTBPNm9acmExQ0RjZVhRbDN5dDNXWWZodnFfOEY5bHk3d0JrbzEyY2FxRWlCWWc3VkwzUlVDS0M1VmZma3daTnV4V25YRkJuQVRaQTd5djMwSnl0YURyLVZETklNRllhdw?oc=5","date":"2025-09-25","type":"deal","source":"Stock Titan","summary":"$200M Bitcoin Deal: Biotech Scilex Trades Semnur Pharma Shares in Groundbreaking Crypto Exchange - Stock Titan","headline":"$200M Bitcoin Deal: Biotech Scilex Trades Semnur Pharma Shares in Groundbreaking Crypto Exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPRzB6NXMta29ELWpSYXhqclQyRXJSaUUtV2djc25vZGVrVnZ6LVotcmlQMHR4Q2N3a00zUEk3dVQ3WHpWRlduSzZBMUZrbVBJd1pDeC1ZWVc1eFVuTGtaaUlGVGxBUWZnQnE3YTREbEgyYldyMWFHaGRkaUtPd1hnWkJXTzI4MHRGaFE0dTItMVgxUQ?oc=5","date":"2025-09-22","type":"pipeline","source":"Yahoo Finance","summary":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously A","headline":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”),","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-04","type":"pipeline","source":"GlobeNewswire","summary":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned - GlobeNewswire","headline":"Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned","sentiment":"neutral"}],"patents":[{"drugName":"ZTlido","drugSlug":"lidocaine","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":10000000},{"drugName":"Qtrypta","drugSlug":"ziconotide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pacira Pharmaceuticals","DURECT Corporation","AcelRx Pharmaceuticals"],"therapeuticFocus":["Pain Management"],"financials":{"source":"sec_edgar+yahoo","revenue":56590000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":56590000,"period":"2024-12-31"},{"value":46743000,"period":"2023-12-31"},{"value":46743000,"period":"2023-12-31"},{"value":38034000,"period":"2022-12-31"},{"value":38034000,"period":"2022-12-31"}],"grossProfit":19654000,"grossProfitHistory":[{"period":"2025-12-31","value":19654000},{"period":"2024-12-31","value":39901000},{"period":"2023-12-31","value":31062000},{"period":"2022-12-31","value":27237000}],"rdSpend":9641000,"rdSpendHistory":[{"period":"2025-12-31","value":20710000},{"period":"2024-12-31","value":9641000},{"period":"2023-12-31","value":12746000},{"period":"2022-12-31","value":9054000}],"sgaSpend":266884000,"operatingIncome":-272304000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-272304000},{"period":"2024-12-31","value":-92787000},{"period":"2023-12-31","value":-105431000},{"period":"2022-12-31","value":-50634000}],"netIncome":-72807000,"netIncomeHistory":[{"period":"2025-12-31","value":-358734000},{"period":"2024-12-31","value":-72807000},{"period":"2023-12-31","value":-114331000},{"period":"2022-12-31","value":-23364000}],"eps":-36.48,"epsHistory":[{"period":"2025-12-31","value":-36.48},{"period":"2024-12-31","value":-8.05},{"period":"2023-12-31","value":-44.8},{"period":"2022-12-31","value":-5.95}],"cash":4955000,"cashHistory":[{"period":"2025-12-31","value":4955000},{"period":"2024-12-31","value":3272000},{"period":"2023-12-31","value":3921000},{"period":"2022-12-31","value":2184000}],"totalAssets":92953000,"totalLiabilities":576734000,"totalDebt":124143000,"equity":-207782000,"operatingCashflow":3816000,"operatingCashflowHistory":[{"period":"2025-12-31","value":3816000},{"period":"2024-12-31","value":19349000},{"period":"2023-12-31","value":-20707000},{"period":"2022-12-31","value":-21258000}],"capex":-733000,"capexHistory":[{"period":"2025-12-31","value":-733000},{"period":"2024-12-31","value":-600000},{"period":"2023-12-31","value":-330000},{"period":"2022-12-31","value":-2067000}],"freeCashflow":3083000,"dividendsPaid":null,"buybacks":0,"employees":34,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":30159000,"ebit":-42601000,"ebitda":-41014000,"period":"2025-12-31","revenue":4793000,"epsBasic":null,"netIncome":-33112000,"rdExpense":8168000,"epsDiluted":null,"grossProfit":2179000,"operatingIncome":-37482000},{"sga":188824000,"ebit":-255021000,"ebitda":-253998000,"period":"2025-09-30","revenue":10560000,"epsBasic":-22.17,"netIncome":-257234000,"rdExpense":3899000,"epsDiluted":-22.17,"grossProfit":7231000,"operatingIncome":-186512000},{"sga":19841000,"ebit":-41347000,"ebitda":-40337000,"period":"2025-06-30","revenue":9896000,"epsBasic":-7.42,"netIncome":-42308000,"rdExpense":6187000,"epsDiluted":-7.42,"grossProfit":6624000,"operatingIncome":-20412000},{"sga":28060000,"ebit":-23599000,"ebitda":-22596000,"period":"2025-03-31","revenue":5004000,"epsBasic":-2.26226,"netIncome":-26080000,"rdExpense":2456000,"epsDiluted":-2.26226,"grossProfit":3620000,"operatingIncome":-27898000},{"sga":35406000,"ebit":-6176000,"ebitda":-5172000,"period":"2024-12-31","revenue":14900000,"epsBasic":null,"netIncome":-6460000,"rdExpense":2180000,"epsDiluted":null,"grossProfit":10209000,"operatingIncome":-28378000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.58,"netIncome":null,"rdExpense":null,"epsDiluted":-0.58,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.76,"previousClose":6.58,"fiftyTwoWeekHigh":34.27,"fiftyTwoWeekLow":4.02,"fiftyTwoWeekRange":"4.02 - 34.27","fiftyDayAverage":7.65,"twoHundredDayAverage":13.97,"beta":1.79,"enterpriseValue":163869168,"forwardPE":9.3,"priceToBook":-0.23,"priceToSales":1.57,"enterpriseToRevenue":5.42,"enterpriseToEbitda":-0.61,"pegRatio":0,"ebitda":-267680992,"ebitdaMargin":0,"freeCashflow":24583124,"operatingCashflow":3816000,"totalDebt":132543000,"debtToEquity":0,"currentRatio":0.08,"returnOnAssets":-74.3,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17.6,"institutionHeldPercent":13.9,"sharesOutstanding":7033004,"floatShares":4709862,"sharesShort":169136,"shortRatio":2.91,"shortPercentOfFloat":2.4,"epsTrailing":-36.48,"epsForward":0.73,"revenuePerShare":2.74,"bookValue":-29.75,"officers":[{"age":59,"name":"Dr. Suketu D. Desai Ph.D.","title":"Interim Chief Technical Officer & Senior VP"},{"age":null,"name":"Ms. Gigi  DeGuzman","title":"VP & Chief People Officer"},{"age":65,"name":"Mr. Suresh K. Khemani","title":"Senior VP, Chief Commercial Officer & GM of Scilex Pharma"},{"age":66,"name":"Dr. Dmitri V. Lissin M.D.","title":"Senior VP of Clinical Development and Medical Affairs & Interim Chief Medical Officer"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.scilexholding.com","phone":"650 516 4310"}}